We're thrilled to announce that OMTX is now opening early access to our revolutionary drug discovery platform. After months of internal validation and successful pilot programs, we're ready to expand access to select partners.
What's Available
Early access customers will have the ability to:
- Submit proteins of interest for screening against our 350M+ molecule library
- Receive comprehensive screening results within 2-3 weeks
- Access our proprietary ML models for interaction prediction
- Integrate our data directly into your discovery workflows via API
- Run data access requests through the API, or generate your own datasets with Data Generation, or if you want to learn more and don't know where to get started reach out! contact us to go over how we can help you.
The Scale Advantage
Our platform can screen hundreds of proteins per week against our entire molecular library. This means you can go from hypothesis to actionable data in weeks, not years. We're already generating over 100 billion data points weekly, and this capacity continues to grow.
Who Should Apply
We're looking for partners in:
- Pharmaceutical companies with active discovery programs
- Biotech startups working on novel targets
- Academic institutions conducting translational research
- Research organizations focused on rare diseases
How to Get Access
Early access is limited to ensure we can provide exceptional support to each partner. Contact our team to discuss your specific needs and how OMTX can accelerate your drug discovery efforts. We're particularly interested in partners working on challenging targets where traditional approaches have failed.
